Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pirow Bekker

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
Journal of Inflammation Research|September 16, 2022
ANCA Associated Vasculitis Subtypes: Response [Letter]Peter A Merkel, David R W Jayne, Pirow Bekker
The New England Journal of Medicine|May 27, 2021
Avacopan for the Treatment of ANCA-Associated Vasculitis. ReplyDavid R W Jayne, Peter A Merkel, Pirow Bekker
JAMA|October 19, 2021
Reduced-Dose vs High-Dose Glucocorticoids Added to Rituximab and Remission Induction in ANCA-Associated VasculitisDavid R W Jayne, Peter A Merkel, Pirow Bekker
JMIR Research Protocols|February 24, 2020
Evaluation of the Safety and Efficacy of Avacopan, a C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Treated Concomitantly With Rituximab or Cyclophosphamide/Azathioprine: Protocol for a Randomized, Double-Blind, Active-Controlled, Phase 3 TrialPeter A Merkel, David R Jayne, Chao Wang, et al.
The New England Journal of Medicine|February 17, 2021
Avacopan for the Treatment of ANCA-Associated VasculitisDavid R W Jayne, Peter A Merkel, Thomas J Schall, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 13, 2018
Effect of Disease Activity at Three and Six Months After Diagnosis on Long-Term Outcomes in Antineutrophil Cytoplasmic Antibody-Associated VasculitisSeerapani Gopaluni, Oliver Flossmann, Mark A Little, et al.
Clinical Pharmacology in Drug Development|February 29, 2024
Pharmacokinetic Evaluation of the CYP3A4 and CYP2C9 Drug-Drug Interaction of Avacopan in 2 Open-Label Studies in Healthy ParticipantsShichang Miao, Pirow Bekker, Danielle Armas, et al.
Arthritis and Rheumatism|May 18, 2004
Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexateMark C Genovese, Stanley Cohen, Larry Moreland, et al.
The Lancet. Rheumatology|January 22, 2024
The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trialVibeke Strand, David R W Jayne, Audra Horomanski, et al.
Clinical Kidney Journal|May 2, 2022
C5a receptor inhibitor avacopan in immunoglobulin A nephropathy-an open-label pilot studyAnnette Bruchfeld, Hasan Magin, Patrick Nachman, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Journal of Inflammation Research|September 16, 2022
ANCA Associated Vasculitis Subtypes: Response [Letter]Peter A Merkel, David R W Jayne, Pirow Bekker
The New England Journal of Medicine|May 27, 2021
Avacopan for the Treatment of ANCA-Associated Vasculitis. ReplyDavid R W Jayne, Peter A Merkel, Pirow Bekker
JAMA|October 19, 2021
Reduced-Dose vs High-Dose Glucocorticoids Added to Rituximab and Remission Induction in ANCA-Associated VasculitisDavid R W Jayne, Peter A Merkel, Pirow Bekker
JMIR Research Protocols|February 24, 2020
Evaluation of the Safety and Efficacy of Avacopan, a C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Treated Concomitantly With Rituximab or Cyclophosphamide/Azathioprine: Protocol for a Randomized, Double-Blind, Active-Controlled, Phase 3 TrialPeter A Merkel, David R Jayne, Chao Wang, et al.
The New England Journal of Medicine|February 17, 2021
Avacopan for the Treatment of ANCA-Associated VasculitisDavid R W Jayne, Peter A Merkel, Thomas J Schall, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 13, 2018
Effect of Disease Activity at Three and Six Months After Diagnosis on Long-Term Outcomes in Antineutrophil Cytoplasmic Antibody-Associated VasculitisSeerapani Gopaluni, Oliver Flossmann, Mark A Little, et al.
Clinical Pharmacology in Drug Development|February 29, 2024
Pharmacokinetic Evaluation of the CYP3A4 and CYP2C9 Drug-Drug Interaction of Avacopan in 2 Open-Label Studies in Healthy ParticipantsShichang Miao, Pirow Bekker, Danielle Armas, et al.
Arthritis and Rheumatism|May 18, 2004
Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexateMark C Genovese, Stanley Cohen, Larry Moreland, et al.
The Lancet. Rheumatology|January 22, 2024
The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trialVibeke Strand, David R W Jayne, Audra Horomanski, et al.
Clinical Kidney Journal|May 2, 2022
C5a receptor inhibitor avacopan in immunoglobulin A nephropathy-an open-label pilot studyAnnette Bruchfeld, Hasan Magin, Patrick Nachman, et al.
Pageof 3